[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • METHODS: A retrospective study was performed of all patients with NHL and involvement of the colon in two medical centers.
  • RESULTS: Fourteen patients had primary involvement and 3 secondary.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


2. Wang SL, Liao ZX, Liu XF, Yu ZH, Gu DZ, Qian TN, Song YW, Jin J, Wang WH, Li YX: Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients. World J Gastroenterol; 2005 Oct 7;11(37):5905-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients.
  • AIM: To analyze the clinical features, management, and outcome of treatment of patients with primary intestinal and colonic non-Hodgkin's lymphoma (PICL).
  • Thirty-five patients underwent surgery (including 31 with complete resection), 22 received postoperative chemotherapy or radiotherapy or both.
  • Two patients with rectal tumors underwent biopsy and chemotherapy with or without radiotherapy.
  • In univariate analysis, multiple-modality treatment was associated with a better DFS rate compared to single treatment (P = 0.001).
  • While age, tumor size, tumor site, stage, histology, or extent of surgery were not associated with OS and DFS, use of adjuvant chemotherapy significantly improved DFS (P = 0.031) for the 31 patients who underwent complete resection.
  • Additional radiotherapy combined with chemo-therapy led to a longer survival than chemotherapy alone in six patients with gross residual disease after surgery or biopsy.
  • CONCLUSION: Combined surgery and chemotherapy is recommended for treatment of patients with PICL.
  • [MeSH-major] Colonic Neoplasms / pathology. Intestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270408.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4479699
  •  go-up   go-down


3. Tauro LF, Furtado HW, Aithala PS, D'Souza CS, George C, Vishnumoorthy SH: Primary lymphoma of the colon. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the colon.
  • Primary lymphoma of the colon is a rare tumor of the gastrointestinal (GI) tract and comprises only 0.2-1.2% of all colonic malignancies.
  • The most common variety of colonic lymphoma is non-Hodgkin's lymphoma (NHL).
  • The GI tract is the most frequently involved site, accounting for 30-40% of all extra nodal lymphomas, approximately 4-20% of which are NHL.
  • Therapeutic approaches described in two subsets include: Radical tumor resection (hemicolectomy) plus multi-agent chemotherapy (polychemotherapy) in early stage patients, biopsy plus multidrug chemotherapy in advanced stage patients.
  • Radiotherapy is reserved for specific cases; surgery alone can be considered as an adequate treatment for patients with low-grade NHL disease that does not infiltrate beyond the sub mucosa.
  • Although resection plays an important role in the local control of the disease and in preventing bleeding and/or perforation, it rarely eradicates the lymphoma by itself.
  • Those with limited stage disease may enjoy prolonged survival when treated with aggressive chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Am J Surg. 2009 Jan;197(1):e11-2 [18723150.001]
  • [Cites] Int Surg. 2001 Jan-Mar;86(1):20-5 [11890335.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):291-7 [8071513.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):461-6 [8590847.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):22-33 [16502482.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1005-6; discussion 1006 [18565526.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):257-62 [10962456.001]
  • (PMID = 19794280.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981851
  •  go-up   go-down


Advertisement
4. Garza-Sánchez J, Hernández-Ramírez DA, Rocha-Ramírez JL, Rojas-Illanes M, Parrado-Montaño W, Cancino-López JA, Dorantes-Díaz DE, Jonguitud-Muro LA: [Non Hodgkin lymphoma of the sigmoid colon: case report]. Rev Gastroenterol Mex; 2009 Apr-Jun;74(2):127-31
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma of the sigmoid colon: case report].
  • [Transliterated title] Linfoma no Hodgkin de sigmoides: reporte de un caso.
  • Non-Hodgkin lymphoma (NHL) occurs in extranodal location in approximately 20% of patients with limited stage, high-grade disease.
  • Colon is infrequently involved as a primary location, accounting for 4% of all extranodal NHL and far less than 1% of all colonic malignancies.
  • Colonic NHL differs significantly in terms of presentation, therapy and outcome relative to other more common gastrointestinal sites, like stomach or small bowel.
  • Therapy usually involves resection of the affected colon and regional lymph nodes followed by adjuvant chemotherapy or/and radiotherapy.
  • A sigmoidectomy was realized with histopathologic report of NHL.
  • Systemic adjuvant chemotherapy and abdominal radiation were administered.
  • After a 6 month follow-up from initial procedure he is now asymptomatic with Karnofsky of 90.
  • Therefore a surgeon should consider the possibility of NHL when evaluating such patients.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse. Sigmoid Neoplasms

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666296.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


5. Frankel SR: Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol; 2003 Apr;30(2):300-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
  • The components of the apoptotic pathway are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies.
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are underway to evaluate oblimersen in non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and hormone-refractory prostate cancer.
  • Preclinical data support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia, and breast, small cell lung, gastric, colon, bladder (CML), and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Apoptosis. Down-Regulation / drug effects. Genes, bcl-2 / genetics. Oligonucleotides, Antisense / therapeutic use. Thionucleotides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12720157.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  • [Number-of-references] 45
  •  go-up   go-down


6. Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M: Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy. Intern Med; 2005 May;44(5):476-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.
  • A 56-year-old man was admitted for treatment of non-Hodgkin's lymphoma (NHL).
  • He had undergone a partial small bowel and colon resection and had ileostomy due to bowel perforation induced by chemotherapy.
  • [MeSH-major] Ileostomy. Intestinal Perforation / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Biopsy. Colon / radiography. Colon / radionuclide imaging. Colon / surgery. Follow-Up Studies. Humans. Male. Mediastinum / pathology. Mediastinum / radiography. Mediastinum / radionuclide imaging. Middle Aged. Positron-Emission Tomography. Rupture, Spontaneous. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942098.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Moreno A, Colon-Otero G, Solberg LA Jr: The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard? Oncologist; 2000;5(3):238-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?
  • METHODS: Sixteen textbooks and chemotherapy reference books were reviewed.
  • RESULTS: Sixteen textbooks and chemotherapy reference books reviewed quoted only one prednisone dosage as part of the standard CHOP regimen; the prednisone dosages quoted as standard varied between publications.
  • More than 4,000 eligible non-Hodgkin's lymphoma patients have been treated with the CHOP chemotherapy as part of 43 different clinical trials reviewed.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Practice Patterns, Physicians'. Prednisone / administration & dosage
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Reference Values. Reproducibility of Results. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10884502.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • By further investigation, in 2 cases with localization within transversal part of colon and rectum no other sites of NHL were found.
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • Since the median survival in our group of patients is at the moment 41+ months and the median has not yet been reached, our experience does not confirm literature data claiming bad prognosis of primary NHL of the colon and rectum.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Saleh M: Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story. J Med Assoc Ga; 2003 Winter-Spring;92(1):39-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.
  • The advent of monoclonal antibodies targeted at tumor associated or tumor specific antigens provides a novel approach for the treatment of a broad range of malignancies.
  • The applicability of this strategy has been expanded beyond the treatment of NHL as demonstrated by the clinical application of the chimeric monoclonal antibody directed at the Her2/neu receptor in breast cancer, the epidermal growth factor receptor in colon and head/neck cancer, and the vascular endothelial growth factor in lung and colon cancer, among others.
  • In a variety of settings this strategy demonstrates clinical anti-tumor activity in patients who have failed to respond to or are refractory to conventional cytotoxic chemotherapy.
  • Furthermore, given the modest toxicity of these naked antibodies, they avail themselves as ideal partners for combining with conventional chemotherapy to produce results that often appear to be greater than additive.
  • With the discovery of newer targets and means to manipulate the immunoglobulin molecule to generate tailor made antibody fragments, the field of antibody based targeted therapy of cancer appears to be on the threshold of making major strides in the fight against cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Combined Modality Therapy / methods. Drug Delivery Systems / methods. Drug Evaluation / methods. Drug Therapy, Combination. Humans. Radioimmunotherapy / methods. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12743905.001).
  • [ISSN] 0025-7028
  • [Journal-full-title] Journal of the Medical Association of Georgia
  • [ISO-abbreviation] J Med Assoc Ga
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 63
  •  go-up   go-down


10. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
  • METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
  • All patients were staged by computed tomography scanning and bone marrow examination, in addition to the endoscopic evaluation.
  • RESULTS: All patients were males; 4 were heterosexual, 2 homosexual, and 1 were a hemophilic and an intravenous drug abuser.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • All patients presented "B" symptoms at the time of diagnosis.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • Four patients were treated with systemic chemotherapy with granulocitic growth factor support plus highly active antiretroviral therapy (HAART); 2 of them (cavum and one of the colon) had a prolonged survival with immune reconstitution during 5 and 6 years, respectively, after the diagnosis.
  • The median survival of the patients, which received HAART plus chemotherapy, was 33 months.
  • CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.
  • Early diagnosis followed by chemotherapy plus HAART are necessary to improve the prognosis and the survival of these patients.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


11. Khorana AA, Culakova E, Lyman GH, Francis CW: Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):8019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy.
  • TED rates may be further increased with chemotherapy.
  • We conducted a prospective study to determine incidence of symptomatic TED in cancer outpatients on chemotherapy, and a retrospective analysis of TED rates in cancer patients hospitalized with febrile neutropenia.
  • METHODS: Cancer outpatients initiating chemotherapy were registered at 137 community practices nationwide, and followed prospectively for 4 cycles.
  • Primary outcomes included documented symptomatic venous thrombotic or embolic events.
  • Pulmonary embolism occurred in 9 patients, and 28 patients developed deep venous thrombosis for a TED incidence of 2% over a median follow-up of 2.3 months.
  • Incidence varied significantly by site of disease (p=0.027) with highest rates in Hodgkin's disease (n=4/38 10.5%), pancreatic cancer (n=2/26, 7.7%) and lung cancer (11/365, 3%).
  • Other sites included ovarian cancer (n=3/147, 2%), NHL (n=3/174, 1.7%), colon (n=3/193, 1.6%), and breast (n=7/672, 1%).
  • Patients with TED reported a chemotherapy delay of ≥ 7 days in 44% compared to 23% in the study population (p=0.003, OR 2.73).
  • An additional 1.3% develop TED if hospitalized with complications of chemotherapy.
  • TED can lead to significant delays in chemotherapy.
  • Trials of prophylactic anticoagulation in cancer patients on chemotherapy are warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015837.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rubio-Martínez A, Recasens V, Martos C, Montañés A, García-Carpintero G, Gómez-López L, Rubio-Félix D, Giraldo P: Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients. J Clin Oncol; 2004 Jul 15;22(14_suppl):6707

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors to develop a second neoplasia in a Hodgkin disease cohort patients.
  • : 6707 Background: Hodgkin's lymphoma (HL) is a rare malignancy, incidence rate (IR): 2.4/105 inh/y, 85% can be cured.
  • The importance of late effects of therapy have become more apparent.
  • VARIABLES: demographic data, date of HL diagnosis, histological subtype, stage, treatment schedule (chemotherapy, radiotherapy, combined), date SM diagnosis, subtype and location of cancer.
  • Cohort was stratified according to age, gender and schedule of therapy.
  • Radiotherapy 16.1% (mantle 50%, inverted-Y 11.8 %, both: 1.6%;cobalt 59.3%, linear accelerator 4.2%; total dose 20-36 Gy), chemotherapy 39.8% (ABVD 14.4%, MOPP 15.5%, CMOPP 23.7%, CMOPP/ABVD 18.6%, ABVD/MOPP 15.2%), combined 44%.
  • HL relapsed: 10.1%, mean time: 49 m.
  • Developed a SM 15(12.7%), mean 102.3 m; range 9-285: 11 a non-hematological neoplasia: adenocarcinoma (colon, breast, lung, oropharynx, skin, cavum, parotida. thyroid) and 4 a hematological neoplasia (AML and NHL).
  • The global risk of cancer in HL was 10.0 and 6.5 when only non hematological tumor were considered.
  • CONCLUSIONS: The incidence of SM among long-time survivors of HL is higher than in normal population.
  • In other essays the major risk has been observed in patients treated with radiotherapy either alone or combined with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Levine AM, Quinn DI, Gorospe G, Lenz HJ, Tulpule A: Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies. J Clin Oncol; 2004 Jul 15;22(14_suppl):3008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel VEGF-antisense coumpound (VEGF-AS, Veglin) has been developed, targeting VEGF-A,-C and -D.
  • All failed standard therapy including systemic chemotherapy in 24 (92%), biologics/ immunotherapy in 13 (50%), and radiation in 9 (35%).
  • The most common tumor types accrued were lymphoma (NHL) in 5; sarcoma in 4; renal and AIDS-related Kaposi's sarcoma in 3 each; colon and lung in 2 each.
  • Non-hematologic side effects were grade 1 or 2 and included fatigue, hypotension, and perioral numbness (all <20% of pts).
  • [Formula: see text]: There has been anti-tumor activity in 2 patients with AIDS-related KS (one biopsy-proven CR at level 1), in 1 pt with renal cell (PR), and 1 pt with tumor cutaneous T-cell NHL (PR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Petrakova K, Koukalová H, Soumarová R, Palácov' M, Blažkova S, Vyzula R: Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD). J Clin Oncol; 2004 Jul 15;22(14_suppl):6695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD).
  • Aim of our study was quantification of RR of SM in patients treated by "risk" RT ± CT (mantel field for breast cancer, and thyroid cancer, upper abdomen for stomach cancer, inverted Y or total nodal irradiation for colon cancer, inverted Y for gynecologic cancer) in comparison with patients treated by CT ± "non risk" RT.
  • METHODS: 851 patients (475 men and 376 women) with survival time after HD diagnosis >1 year were treated in MOÚ during 1967-1995.
  • 74 cases of SM developed in the cohort.
  • Rate ratio for NHL could not be established because of no case in the control group.
  • CONCLUSION: The relative risk of solid tumors as second malignancies increased with the time of follow-up.
  • Treatment by "risk RT" increases RR of breast cancer, colorectal cancer, gynecologic cancer and slightly thyroid cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.
  • : e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.
  • We report long term follow up of 71 cases of primary GI NHL treated with chemotherapy and/or surgery.
  • The 8 patients with MALT were treated with single agent chemotherapy; 7 (88%) are alive at median follow up of 8.5 years (2-16).
  • Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.
  • Primary sites of DLBCL were stomach 35 (67%), small bowel 11 (21%) & colon 6 (12%).
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.
  • 2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.
  • Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).
  • 5 deaths in the DLBCL group were not related to cancer or treatment.
  • All deaths in the T cell group were due to progressive disease.
  • There was no difference in survival between patients treated with chemotherapy only and those who also underwent surgery.
  • CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.
  • However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.
  • A novel therapeutic approach is required to improve outcome in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Aggarwal S, Prakhar P, Kohli S, Negi A, Jauhari M, Bhalla S: Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India. J Clin Oncol; 2009 May 20;27(15_suppl):e19566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India.
  • Out of a total of 16,500 cases, NHL was reported in 154 (0.93%)cases.
  • The type of NHL was B-Cell type (CD-20+ve) in 132(85%) and T-Cell type (CD 3+ve) in 22 (15%) cases.
  • In extra-nodal group of NHL patients the no.
  • Out of 77 extra-nodal cases, 31(20%) were GIT NHL (Stomach -16, Colon-8, Ileum-4, and Duodenum-3) and out of the rest 46 extra-nodal cases the site of origin was - head & neck-14, skin n soft tissues -8, primary CNS-6, testicular-4, para-spinal- 3, breast mass-3, perinephric-2, bones-2 and 1 each in cervix, lung mass, liver and cervical plexus.
  • METHODS: A detailed analysis of 31 GIT NHL cases was carried out.
  • 28 out of 31 were B-Cell type and 3 were T-Cell type.
  • In 2 patients the type of lymphoma could not be ascertained.
  • Bone marrow infiltration was present in 2 out of 31 cases of GIT Lymphoma.
  • Surgery was carried out in 15 of 31 GIT NHL cases and these were arising from Colon, Ileum and Duodenum.
  • No surgery was performed in patients with stomach lymphoma.
  • RESULTS: Of all the extra-nodal cases chemotherapy was given to 39 patients - R-CHOP = 20 patients, CHOP = 13 patients, high dose MTX in primary CNS NHL = 6 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Genovese AM, Fedele F, Barbera A, Fonti MT, Rossitto M, De Jesi F, Ciccolo A: [Primary non-Hodgkin's lymphoma of the colon: a rare but possible location. Therapeutic approach. Description of a clinical case and review of the literature]. Minerva Chir; 2002 Apr;57(2):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the colon: a rare but possible location. Therapeutic approach. Description of a clinical case and review of the literature].
  • [Transliterated title] Linfoma non-Hodgkin primitivo del colon: una rara, ma possibile localizzazione. Iter terapeutico. Descrizione di un caso clinico e revisione della letteratura.
  • On the basis of a case of large cell, highly malignant, non-Hodgkin's lymphoma of the colon, the authors describe the special features of this rare location; the general aspects of this rare pathology of the colon are then considered.
  • The clinical case relates to a large cell, highly malignant, non-Hodgkin's colic lymphoma located in the caecum at two thirds proximally of the ascending colon of which it occupies half the lumen.
  • In disaccord with certain literature reports, surgical treatment was considered by the authors the key to the therapeutic approach.
  • Surgical exeresis should be as radical as possible to permit complementary therapies (chemotherapy and radio-therapy) to act with most effectiveness and thus offer the patient a better life.
  • [MeSH-major] Lymphoma, Large-Cell, Immunoblastic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11941297.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 5
  •  go-up   go-down


18. Nomura K, Matsumoto Y, Yoshida N, Taji S, Wakabayashi N, Mitsufuji S, Horiike S, Morita M, Okanoue T, Taniwaki M: Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma. World J Gastroenterol; 2004 Mar 1;10(5):765-6
Hazardous Substances Data Bank. RIFAMPIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma.
  • A 74-year-old man was admitted to the hospital because of chemotherapy for relapsed non-Hodgkin's lymphoma (NHL).
  • The patient became febrile and experienced diarrhea after chemotherapy.
  • Although ceftazidime and amikacin sulfate were administered as empiric therapy, diarrhea was continued.
  • To rule out the presence of an additional cause of diarrhea, colon fibroscopic examination was performed.
  • It revealed multiple deep ulcerative lesions at right side colon, surface erosive and minute erosive lesions in all continuous colon.
  • [MeSH-major] Antibiotics, Antitubercular / administration & dosage. Clostridium difficile / drug effects. Enterocolitis / drug therapy. Lymphoma, Non-Hodgkin / complications. Rifampin / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14991957.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antitubercular; VJT6J7R4TR / Rifampin
  • [Other-IDs] NLM/ PMC4716928
  •  go-up   go-down


19. Vardy J, Wong E, Izard M, Clifford A, Clarke SJ: Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs; 2002 Mar;13(3):327-30
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common associated cancers are ovarian, lung, pancreatic, stomach, colon and non-Hodgkin's lymphoma.
  • Radiotherapy is the mainstay of treatment for early nasopharyngeal cancer, but combination chemoradiotherapy is becoming more common for patients with advanced disease since the Intergroup trial 0099 demonstrated improved progression-free survival and overall survival for chemoradiotherapy.
  • [MeSH-major] Amifostine / adverse effects. Anaphylaxis / chemically induced. Dermatomyositis / drug therapy. Dermatomyositis / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation-Protective Agents / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dermatomyositis.
  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11984077.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  • [Number-of-references] 7
  •  go-up   go-down


20. Fanale MA, Younes A: Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs; 2007;67(3):333-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
  • Antibody-based therapeutic approaches have had a significant impact in the treatment of non-Hodgkin's lymphoma (NHL).
  • Rituximab's development as an anti-CD20 antibody heralded a new era in treatment approaches for NHL.
  • While rituximab was first shown to be effective in the treatment of relapsed follicular lymphoma, it is now standard monotherapy for front-line treatment of follicular lymphoma, and is also used in conjunction with chemotherapy for other indolent, intermediate and aggressive B-cell lymphomas.
  • The development of rituximab has led to intense interest in this type of therapeutic approach and to development and approval of the radioimmunoconjugates of rituximab, (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, which have added to the repertoire of treatments for relapsed follicular lymphoma and increased interest in developing other conjugated antibodies.
  • Since rituximab is a chimeric antibody, there is a need to develop fully humanised antibodies, such as IMMU-106 (hA20), in order to minimise infusion reactions and eliminate the development of human antibodies against the drug.
  • Further clinical evaluation of antibodies has been based largely on our knowledge of antigen expression on the surface of lymphoma cells and has led to the development of antibodies against CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD52 (alemtuzumab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [iratumumab]), and CD40 (SGN-40).
  • Furthermore, the VEGF (vascular endothelial growth factor) inhibitor bevacizumab, which was first approved for the treatment of colon cancer is currently under investigation in NHL, and agonists rather than antibodies to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) [rApo2L/TRAIL, HGS-ETR1{mapatumumab}, HGS-ETR2] are currently being investigated as treatments for both advanced solid tumours and NHL.
  • Knowledge of the ability of cancer cells to become resistant to a targeted therapy by activating an alternative pathway to evade apoptosis has driven studies that combine antibodies such as epratuzumab plus rituximab (ER) or ER plus chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) [ER-CHOP], inotuzumab ozogamicin plus rituximab, alemtuzumab plus CHOP (CHOP-C), bevacizumab plus rituximab, and now the combination of rApo2L/TRAIL plus rituximab.
  • As a result of the expansion of research in this area, several treatment-specific adverse effects have been noted, including infusion-related reactions for rituximab, myelosuppression secondary to (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, and immunosuppression leading to infectious complications for alemtuzumab.
  • Also, soluble forms of the antigens (sCD30) are now being investigated as potential mechanisms of resistance to antibody treatments by binding the antibody before the drug can bind to the lymphoma cell.
  • Antibody-based therapeutic approaches have already had a profound impact on the treatment of NHL, and it is almost certain that, as their clinical development progresses, we will continue to refine the optimum methods of incorporating these drugs in NHL treatment in order to offer our patients the best clinical benefits.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, Surface / drug effects. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Receptors, Tumor Necrosis Factor / drug effects
  • [MeSH-minor] Drug Delivery Systems. Drug Design. Drugs, Investigational / pharmacology. Drugs, Investigational / therapeutic use. Humans. Neovascularization, Pathologic / drug therapy. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4940-7 [9354461.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):618-24 [9401075.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] Eur J Immunol. 1995 Dec;25(12):3332-41 [8566020.001]
  • [Cites] Immunol Lett. 2003 Jul 3;88(1):57-62 [12853163.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):535-42 [10331480.001]
  • [Cites] Annu Rev Immunol. 2003;21:231-64 [12427767.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):311-24 [12787568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7946-51 [15905329.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4267-72 [12543862.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):2-17 [10647992.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Haematologica. 2003 Sep;88(9):1002-12 [12969808.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2576-81 [8637916.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6325-32 [16155015.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):501-10 [16098063.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Dec;3(4):261-86 [14683470.001]
  • [Cites] Blood. 1994 Feb 1;83(3):793-8 [7507734.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5215-22 [16033839.001]
  • [Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]
  • [Cites] Int Immunol. 1996 Nov;8(11):1707-14 [8943565.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Cell Death Differ. 2003 Oct;10(10):1121-5 [14502235.001]
  • [Cites] Immunol Today. 1994 Jul;15(7):321-31 [7522010.001]
  • [Cites] Cell. 2001 Feb 23;104(4):487-501 [11239407.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3355-62 [9363866.001]
  • [Cites] J Clin Immunol. 2003 Sep;23(5):317-32 [14601641.001]
  • [Cites] Blood Rev. 1996 Jun;10(2):111-27 [8813343.001]
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):171-5 [10629073.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23 ):14363-7 [9603945.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):458-67 [12879461.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Clin Pharmacokinet. 1995 Feb;28(2):126-42 [7736688.001]
  • [Cites] Cancer. 2006 May 15;106(10):2148-57 [16598754.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3793-803 [10577851.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):250-6 [12950233.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2A):401-6 [1693265.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4297-306 [9373240.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J R Soc Med. 2005 Apr;98 (4):146-52 [15805554.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1088-95 [15657401.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Haematologica. 2005 May;90(5):702-3 [15921394.001]
  • [Cites] Eur J Immunol. 2002 Jan;32(1):163-73 [11754357.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):10-4 [9589458.001]
  • [Cites] Immunol Today. 1993 Jun;14(6):243-6 [8397764.001]
  • [Cites] Blood. 2003 Jul 1;102(1):284-8 [12649132.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3918-28 [11579112.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1606-12 [12738671.001]
  • [Cites] Eur J Immunol. 1995 Nov;25(11):3023-9 [7489738.001]
  • [Cites] Nat Med. 2001 Feb;7(2):151-2 [11175837.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]
  • [Cites] Int Immunol. 2004 Jan;16(1):119-29 [14688067.001]
  • [Cites] Leuk Lymphoma. 1995 Dec;20(1-2):27-38 [8750620.001]
  • [Cites] Curr Opin Oncol. 1999 Sep;11(5):364-9 [10505772.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] Clin Lymphoma. 2003 Mar;3(4):257-9 [12672278.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Cancer. 1997;76(9):1163-9 [9365164.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Mol Interv. 2005 Dec;5(6):368-80 [16394252.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:140-74 [15564720.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4711-6 [15483015.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • (PMID = 17335294.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Surface; 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 0 / Receptors, Tumor Necrosis Factor; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 110
  •  go-up   go-down


21. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • We included adult patients, with ELISA and Western blot test positive for HIV, and primary malignant tumors located in the colon or rectum.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • For NHL average survival was 29 months, and 12 months for CR-ACA.
  • Early in our experience, tumors frequently found in immunoincompetent patients were detected (NHL).
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • Therefore, these tumors may be associated with the grade of immunosuppression induced during the course of the HIV infection and with a tumorigenic effect of the HIV on the colonic epithelium.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / surgery. Adenocarcinoma / complications. Adult. Aged. Female. Humans. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Survival Rate


22. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • Forty patients with primary NHL in the small and large intestine were studied retrospectively.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • The ileocaecal region has the highest involved rate (13 of 25 patients, 52.0%), followed by colon (7 of 25 patients, 28.0%) and rectum (3 of 25 patients, 12.0%).
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol; 2005 Sep;55(3):231-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Older patients (with serious co-morbidity) with non-small cell lung cancer or prostate cancer underwent surgery less often than younger patients.
  • Elderly with stage III colon cancer, small cell lung cancer, FIGO II or III ovarian cancer or non-Hodgkin's lymphoma (NHL) received (adjuvant) chemotherapy less often, probably because of the higher rate of haematological complications.
  • In general, elderly did not suffer from more complications than younger patients, except for cardiac complications (colorectal cancer and NHL) and postoperative death (non-small cell lung cancer).
  • For most tumours relative survival was lower for the elderly, except for patients with colon cancer, prostate cancer or indolent NHL.
  • Future prospective studies should investigate whether the guidelines for cancer treatment should be adjusted for elderly with serious co-morbidity.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979890.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A B-cell non-Hodgkin's lymphoma (NHL) was diagnosed from biopsies of the stomach and liver.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Anile M, Venuta F, Diso D, De Giacomo T, Rendina EA, Rolla M, Ruberto F, Liparulo V, Aratari MT, Di Stasio M, Ricella C, Vitolo D, Longo F, Coloni GF: Malignancies following lung transplantation. Transplant Proc; 2007 Jul-Aug;39(6):1983-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, among the complications related to the continuous administration of immunosuppressive drugs, malignancy plays an important role.
  • Five patients (4.2%) developed malignancy and the mean time of occurrence after the transplantation was 46.4+/-23 months.
  • The tumors were as follows: laryngeal cancer (radiotherapy), colon cancer (surgery plus adjuvant chemotherapy), gastric cancer (surgery plus adjuvant chemotherapy), endobronchial non-Hodgkin lymphoma (NHL) (endoscopic resection plus chemoradiotherapy), and cutaneous and visceral Kaposi's sarcoma (KS) (chemotherapy).
  • All patients have reduced the dose of immunosuppressive drugs; in 1 of them, tacrolimus was changed to rapamycin.
  • The 2 patients with NHL and KS are alive at 6 and 9 months, respectively, without signs of recurrence.
  • [MeSH-minor] Humans. Lymphoma / mortality. Retrospective Studies. Sarcoma, Kaposi / mortality. Survival Analysis


26. Doolabh N, Anthony T, Simmang C, Bieligk S, Lee E, Huber P, Hughes R, Turnage R: Primary colonic lymphoma. J Surg Oncol; 2000 Aug;74(4):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • BACKGROUND AND OBJECTIVES: The colon is a rare location for gastrointestinal non-Hodgkin's lymphoma (NHL).
  • This study was undertaken to identify risk factors, presentation, treatment, and prognosis for primary colonic lymphoma (PCL) through review of a large tertiary care hospital system experience.
  • METHODS: A retrospective review of all patients with colonic malignancy and NHL was performed using pathology and cancer registry databases from January 1989 to December 1998.
  • Criteria for inclusion were no evidence of extraperitoneal disease, no leukemic or lymphomatous abnormalities in the blood, and disease confined to the colon.
  • They represented 1.4% of all NHL, 14% of gastrointestinal NHL and 0.9% of all colonic malignancies diagnosed during this period.
  • Six of 7 patients received adjuvant chemotherapy.
  • CONCLUSIONS: The colon is a rare location for NHL.
  • Patients' frequently present with non-specific abdominal pain, this leads to lengthy delays in diagnosis.
  • Surgery is the most widely utilized form of therapy.
  • Although adjuvant therapy is frequently utilized, its' impact on survival is unclear.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10962456.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Psyrri A, Papageorgiou S, Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol; 2008 Dec;19(12):1992-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management.
  • Gastrointestinal lymphoma is the most common form of extranodal lymphoma, accounting for 30%-40% of cases.
  • The most commonly involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are diffuse large B-cell lymphoma (DLBCL) and marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).
  • Helicobacter pylori infection has been implicated in the pathogenesis of MALT gastric lymphoma, but its role in gastric diffuse large B-cell non-Hodgkin's lymphoma (NHL) is controversial.
  • The therapeutic approach for patients with gastric NHL has been revised over the last 10 years.
  • Conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has replaced gastrectomy as standard therapy in cases with DLBCL.
  • Nevertheless, various therapeutic aspects for primary gastric lymphomas are still controversial and several questions remain unanswered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5061-6 [16051953.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6415-20 [16155028.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1345-53 [16174856.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8442-6 [16293875.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):721-6 [16556173.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2096-101 [17071482.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2110-4 [17071484.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2140-6 [17071488.001]
  • [Cites] Oncology. 2006;70(6):411-7 [17220639.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Gut. 2007 Dec;56(12):1685-7 [17639089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Hematol Oncol. 2000 Mar;18(1):15-9 [10797526.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] J Clin Gastroenterol. 1994 Mar;18(2):99-104 [8189031.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Hematol Oncol. 1995 May-Jun;13(3):153-63 [7622145.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):3-11 [8988720.001]
  • [Cites] Histopathology. 1997 May;30(5):425-9 [9181363.001]
  • [Cites] Ann Oncol. 1997 May;8(5):419-21 [9233518.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):979-85 [9402171.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):531-41 [10342580.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5785-94 [10523859.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] Acta Haematol. 2005;113(2):97-103 [15802887.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Recent Results Cancer Res. 2000;156:99-103 [10802868.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):95-102 [11145257.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1600-9 [11250988.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B100-5 [11757688.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1094-8 [12176789.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1120-7 [12176793.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2003 May 15;101(10):3875-6 [12531812.001]
  • [Cites] Gut. 2003 Jun;52(6):912-3 [12740354.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1086-90 [15205203.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Oncology. 2004;66(6):476-80 [15452377.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):391-7 [3840030.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1153-64 [2349966.001]
  • [Cites] Eur J Cancer. 1990;26(7):855 [2145918.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Histopathology. 1992 Jan;20(1):29-34 [1737623.001]
  • [Cites] Lancet. 1992 Apr 4;339(8797):834-5 [1347858.001]
  • [Cites] Histopathology. 1992 Nov;21(5):415-21 [1452124.001]
  • [Cites] Oncology. 1992;49(6):484-8 [1465289.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 18647965.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2733120
  •  go-up   go-down


28. Radić-Kristo D, Planinc-Peraica A, Ostojić S, Vrhovac R, Kardum-Skelin I, Jaksić B: Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics. Coll Antropol; 2010 Jun;34(2):413-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics.
  • Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas with an increasing incidence.
  • The incidence, clinicopathologic characteristics, treatment and survival were assessed in 39 successive, newly diagnosed PGI-NHL patients (23 male and 16 female) treated at "Merkur" University Hospital.
  • The most common site of PGI-NHL was stomach (n = 29, 74%), followed by small intestine (n = 5, 13%), and colon and rectosigmoid (n = 5, 13%).
  • According to World Health Organization (WHO) classification, 29 (87%) patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal zone B-cell lymphoma-mucosa associated tissue (MALT).
  • Twenty-six (66%) patients underwent surgical resection followed by chemotherapy, ten (26%) were treated with chemotherapy alone, and three (8%) were treated surgically.
  • Patients with localized lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years.
  • In conclusion, our patient group was comparable to other literature reports on PGI-NHL patients according to clinicopathologic characteristics.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / epidemiology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Female. Humans. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Rectal Neoplasms / epidemiology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Retrospective Studies. Sigmoid Neoplasms / epidemiology. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Survival Rate. Young Adult


29. Aleman BM, Haas RL, van der Maazen RW: Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract.
  • In patients with gastrointestinal lymphoma the most frequently involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL).
  • The role of radiotherapy is most definite in early stage gastric lymphoma.
  • The therapeutic approach for patients with gastric Non Hodgkin lymphoma (NHL) has changed significantly over the last decades.
  • The primary treatment of limited gastric MALT lymphoma consists of Helicobacter pylori eradication.
  • In patients with gastric DLBCL conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has become the therapy of choice.
  • [MeSH-major] Intestinal Neoplasms / radiotherapy. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Radiotherapy, Intensity-Modulated. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Chemotherapy, Adjuvant. Dose Fractionation. Helicobacter pylori / pathogenicity. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206106.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 46
  •  go-up   go-down


30. Gonzalez QH, Heslin MJ, Dávila-Cervantes A, Alvarez-Tostado J, de los Monteros AE, Shore G, Vickers SM: Primary colonic lymphoma. Am Surg; 2008 Mar;74(3):214-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • Surgical resection of primary colonic lymphoma can be an important therapeutic tool.
  • From January 1990 to June 2002, a total of 15 patients with primary colonic lymphoma were identified from the tumor registry at University of Alabama at Birmingham and retrospectively reviewed under Institutional Review Board approved protocol.
  • Demographic data, clinical features, treatment method (surgery and/or chemotherapy), recurrence rate, and survival were analyzed.
  • Preoperative diagnosis of lymphoma was made in 13 patients (87%) with colonoscopy and biopsy.
  • The most common disease location was the cecum (60%), followed by the right colon (27%), and the sigmoid colon (13%).
  • LDH returned to normal after treatment in all patients.
  • Eighty-seven per cent had negative margins at the time of operation.
  • Twelve patients received postoperative chemotherapy (80%).
  • According to the clinical classification of primary non-Hodgkin lymphoma (NHL) of the gastrointestinal tract (Lugano, 1993) all patients corresponded to stage IE.
  • Surgical resection of localized, primary colonic lymphoma provides excellent local disease control and should be considered a primary treatment option.
  • The role of chemotherapy remains controversial depending on the grade, stage, and extension of residual disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Colectomy / methods. Female. Humans. Length of Stay / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376684.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol; 2009 Aug;7(8):874-81
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
  • BACKGROUND & AIMS: Although anti-tumor necrosis factor (TNF) therapy can effectively treat Crohn's disease (CD), there is concern that it might increase the risk of non-Hodgkin's lymphoma (NHL).
  • A meta-analysis was performed to determine the rate of NHL in adult CD patients who have received anti-TNF therapy and to compare this rate with that of a population-based registry and a population of CD patients treated with immunomodulators.
  • Inclusion criteria included randomized controlled trials, cohort studies, or case series reporting on anti-TNF therapy in adult CD patients.
  • Standardized incidence ratios (SIR) were calculated by comparing the pooled rate of NHL with the expected rate of NHL derived from the Surveillance Epidemiology & End Results (SEER) database and a meta-analysis of CD patients treated with immunomodulators.
  • Among anti-TNF treated subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years).
  • Compared with the expected rate of NHL in the SEER database (1.9 per 10,000 patient-years), anti-TNF treated subjects had a significantly elevated risk (SIR, 3.23; 95% confidence interval, 1.5-6.9).
  • When compared with the NHL rate in CD patients treated with immunomodulators alone (4 per 10,000 patient-years), the SIR was 1.7 (95% confidence interval, 0.5-7.1).
  • CONCLUSIONS: The use of anti-TNF agents with immunomodulators is associated with an increased risk of NHL in adult CD patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 1;19(3):295-301 [14984376.001]
  • [Cites] Risk Anal. 2009 Jan;29(1):121-36 [18826414.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Inflamm Bowel Dis. 2004 Mar;10(2):91-6 [15168807.001]
  • [Cites] Digestion. 2004;70(1):3-9 [15297773.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2308-12 [11007233.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Inflamm Bowel Dis. 2001 May;7 Suppl 1:S17-22 [11380038.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3):608-12 [12650795.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):402-13 [14762776.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Aug;96(8):548-54; 554-8 [15449986.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):912-20 [15476155.001]
  • [Cites] Inflamm Bowel Dis. 1999 May;5(2):119-33 [10338381.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):164-8 [15720356.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Korean J Gastroenterol. 2005 Jul;46(1):48-55 [16030404.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jan;18(1):11-6 [16357613.001]
  • [Cites] Gut. 2006 Feb;55(2):228-33 [16120759.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1054-61 [16618399.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1837-41 [17041753.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80 [17311600.001]
  • [Cites] Gut. 2007 Sep;56(9):1232-9 [17299059.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:346-55 [17804562.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):769-79 [17628557.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9 [17904915.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):391-3 [18490372.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53 [18550004.001]
  • [Cites] Am J Gastroenterol. 2008 Aug;103(8):2015-22 [18564113.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139 [19465159.001]
  • (PMID = 19558997.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK078678-02; United States / NIDDK NIH HHS / DK / K23 DK078678; United States / NIDDK NIH HHS / DK / K23 DK078678-02; United States / NIDDK NIH HHS / DK / K23DK078678
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS184443; NLM/ PMC2846413
  •  go-up   go-down


32. Dalal L: Primary multifocal non-Hodgkin lymphoma of the colon successfully treated with chemotherapy. Gastrointest Endosc; 2008 Nov;68(5):1005-6; discussion 1006
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multifocal non-Hodgkin lymphoma of the colon successfully treated with chemotherapy.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565526.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement